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ABSTRACT
Nicotine can cause atherosclerosis by activating nuclear factor-kB (NF-kB) pathway 
lead to induce proinflammatory cytokines release as C-reactive protein (CRP) main 
regulators. The increase of CRP can induce reactive oxygen species (ROS) and increase 
of malondialdehyde (MDA). Quercetin has been proven to have antiinflammatory and 
antioxidant effects. This study was conducted to evaluate  effect of quercetin on serum 
CRP and MDA concentrations in rats induced by nicotine. This was a true experimental 
study with post test only control group design. Thirty six of male Wistar rats were divided 
into six groups. Group I as normal control received 1 mL/kg BW of NaCl 0.9% solution. 
Group II as negative control received 2 mg/kg BW of nicotine and Group III as positive 
control received 2 mg/kg BW of nicotine and atorvastatin at dose of 5 mg/kg BW. Group 
IV-VI as treatment groups received 2 mg/kg BW of nicotine and quercetin at dose of 
25; 50 or 100 mg/kg BW, respectively. Nicotine was given subcutaneously whereas 
atorvastatin and quercetin were given orally once per day for 28 days, consecutively. 
Serum CRP and MDA concentrations were measured using Rat hs-CRP ELISA kit and 
TBARS assay kit, respectively. Data were analyzed using analysis of variance (ANOVA) 
continued using LSD post-hoc test. The results showed that quercetin reduced serum CRP 
and MDA concentrations in dose dependent manner. Serum CRP concentration on Group 
V (173.39 ± 34.85 ng/mL) and Group VI (114.15 ± 43.62 ng/mL) were significantly 
lower than that Group II (244.77 ± 37.95 ng/mL) (p<0.05). Furthermore,  serum MDA 
concentration on Group IV (5.95 ± 0.11 mmol/mL), Group V (3.93 ± 0.09 mmol/mL) 
and Group VI (2.14 ± 0.09 mmol/mL) were significantly lower than that Group II (7.29 ± 
0.06 mmol/mL) (p<0.05). In conclusion, quercetin reduces the nicotine-induced oxidative 
status in rats.
ABSTRAK
Nikotin dapat menyebabkan atherosclerosis dengan mengaktifkan jalur nuclear factor-
kB (NF-kB) yang menginduksi pelepasan sitokin proinflamasi sebagai regulator utama 
C-reactive protein (CRP). Kenaikan CRP dapat menginduksi reactive oxygen species (ROS) 
dan meningkatkan malondialdehid (MDA). Quersetin terbukti memiliki efek antiinflamasi 
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dan antioksisdan. Penelitian ini dilakukan untuk mengkaji efek quersetin terhadap kadar 
serum CRP dan MDA tikus yang diinduksi nikotin. Penelitian ini merupakan penelitian 
eksprimental murni menggunakan rancangan post test only control. Tiga puluh enam 
ekor tikus dibagi menjadi enam kelompok. Kelompok I sebagai control normal mnerima 
larutan NaCl 0.9% 1 ml/kg BB. Kelompok II sebagai control negatif menerima nikotik 
2 mg/kg BB. Kelompok III sebagai control positif menerima nikotin 2 mg/kg BB dan 
atorvastatin 5 mg/kg BB. Kelompok IV-VI sebagai kelompok perlakuan menerima nikotin 
2 mg/kg BB dan quersetin berturut-turut 25; 50 dan 100 mg/kg BB. Nikotin diberikan 
secara subkutan sedangkan atorvastatin dan quersetin diberikan secara oral. Kadar CRP 
dan MDA serum ditetapkan menggunakan  Rat hs-CRP ELISA kit dan TBARS assay kit. 
Data yang diperoleh dianalisis dengan analisis varian (ANAVA) dilanjutkan dngan tes LSD 
post-hoc. Hasil penelitian menunjukkan quersetin menurunkan kadar CRP dan MDA yang 
tergantung dosis. Kadar CRP serum Kelompok V (173,39 ± 34,85 ng/mL) dan Kelompok 
VI (114,15 ± 43,62 ng/mL) lebih rendah secara nyata dari Kelompok II (244,77 ± 37,95 
ng/mL) (p<0,05). Selajutnya,  kadar MDA serum MDA pada Kelompok IV (5,95 ± 0,11 
mmol/mL), Kelompok V (3,93 ± 0,09 mmol/mL) dan Kelompok VI (2,14 ± 0,09 mmol/
mL) lebih endah secara nyata dari Kelompok II (7,29 ± 0,06 mmol/mL) (p<0,05). Dapat 
disimpulkan, quersetin menurunkan status oksidatif tikus yang diinduksi nikotin.
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INTRODUCTION
Cigarette smoking has become an 
unhealthy life style almost all over the world.1 
Concerning of one million smokers nowadays, 
there are about 500 thousand smokers who 
will die faster. The epidemiology studies 
estimated that 1 from 3 smokers died due 
to the cardiovascular disease.2,3 The main 
substance which has addictive characteristic 
in cigarette is nicotine.4,5 Nicotine exposure 
on smokers is anticipated to play a significant 
role in various cardiovascular diseases where 
endothelial dysfunction appears as the initial 
sign. Endothelial dysfunction represents the 
early sign of atherosclerosis disease which is 
known as inflammation disease on vascular 
wall.3,6-10
Nicotine can trigger the inflammation 
because it has direct effect on neutrophil 
and macrophage by activating nicotinic 
acetylcholine receptor (nAChR) on nerves 
cell and non nerves cell such as monocyte 
and endothelium. Nicotine binds to activated 
macrophage’s nAChR, furthermore it will 
activate nuclear factor-κB (NF-κB). The 
activation of NF-κB on macrophage causes the 
proliferation and migration of vascular smooth 
muscle cells (VSMC), the production of 
inflammatory mediators e.g. cyclooxygenase 
2 (COX-2), prostaglandin E2 (PGE2), tumor 
necrosis factor-α (TNF-α), interleukin-
1β (IL-1β), inducible nitric oxide synthase 
(iNOS), and also the expression of adhesion 
molecules. The release of proinflammatory 
cytokines to inflammatory sites will trigger 
the C-reactive protein (CRP) synthesis by 
macrophage.6,8
Synthesis of CRP triggers the increase of 
free radicals in the body which is known as 
oxidative stress.6 Oxidative stress can cause 
endothelial dysfunction by deactivating nitric 
oxide (NO) directly, thus it will decrease its 
bioavailability. It can happen due to superoxide 
anion (O2
-) which is one of the very reactive 
free radicals type that binds directly to NO 
and performs peroxynitric.11 Besides that, 
oxidative stress causes tetrahidropbiopterin 
(BH4) oxidation as one of the NO synthetic 
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cofactor. This oxidation causes endothelial 
nitric oxide synthase (eNOS) uncoupling and 
results in the decrease of eNOS expression 
and NO production.12 Despite causing eNOS 
expression decrease, oxidative stress promotes 
endothelial cell membranes damage through 
the mechanism of lipid peroxidation formation 
marked by the increase of malondialdehyde 
(MDA) concentration in the body.13-15
Atherosclerosis disease induced by 
inflammation can be prevented by giving the 
antiinflammation and antioxidant treatments. 
Quercetin is a flavonol which is mostly 
found in fruits and vegetables such as apple, 
black tea, and onion.16,17 Quercetin has 
antiatherosclerosis and antithrombosis effects 
because of its ability as antioxidant, anti 
platelet, and antiinflammation.18 Quercetin 
as an antiinflammation works by blocking 
NF-κB signal, resulting in decreasing 
the protein inhibitor (IκBα and IκBβ) 
phosphorylation.19,20 It can degrade the NF-κB 
transcription factor and cytokines expression 
significantly so that it prevents the increase 
of CRP concentration.20 In addition, quercetin 
works as an antioxidant by catching ROS as 
the main cause of oxidative stress so that it 
can prevent NO production decrease and 
the increase of MDA concentration.21 This 
study was conducted to evaluate the effects 
of quercetin on the concentration of CRP and 
MDA in nicotine-induced male Wistar rats.
MATERIALS AND METHODS 
Chemicals 
Nicotine bitartrate dyhidrate was obtained 
from Nacalai Tesque Inc., Japan. Nicotine 
stock solution was prepared at concentration 
of 2 mg/mL in NaCl 0.9% solution. 
Atorvastatin and quercetin were obtained 
from Sigma-Aldrich, Singapore. Atorvastatin 
and quercetin stock solutions were prepared 
at concentration of 100 mg/mL in sodium 
carboxy methylcellulose (Na-CMC) 0.5% 
solution. All of the stock solutions were stored 
in glass bottle at 4 oC for no longer than 30 
days. 
Animal and experimental design 
This is a true experimental study with post 
test only control group design. Thirty six male 
Wistar rats whose weight ranged between 
100 and 150g and age of 5 weeks obtained 
from the Integrated Research and Testing 
Laboratory (LPPT), Universitas Gadjah Mada 
were used in this study. The rats were housed 
in individual cages that were well ventilated 
under 12-hour cycles of light and dark 
condition at room temperature. They were 
fed a standard food and provided free access 
to water ad libitum. After acclimatization 
period of one week, the rats were divided into 
six groups with 6 rats in each group. Group 
I as normal control received 1 mL/kg BW 
of NaCl 0.9% solution. Group II as negative 
control received 2 mg/kg BW of nicotine and 
Group III as positive control received 2 mg/
kg BW of nicotine and atorvastatin at dose 
of 5 mg/kg BW. Group IV-VI as treatment 
groups received 2 mg/kg BW of nicotine 
and quercetin at dose of 25; 50 or 100 mg/
kg BW, respectively.  The nicotine dosage was 
freshly prepared in NaCl 0.9% solution and 
subcutaneously injected once per day for 28 
days consecutively at 11.00 AM. Whereas, 
the atorvastatin and quercetin dosages were 
freshly prepared in Na-CMC 0.5% solution 
and orally administered once per day for 28 
days consecutively, 3 hours before nicotine 
injection (at 08.00 AM).
Serum CRP and MDA examinations 
On day 35, three hours after the last 
intervention, rats were anesthesized using 
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ketamine and diazepam subcutaneously 
and then were fixated. Blood samples were 
collected from the rats and placed to the 
freezer for over 2 hours at room temperature 
or overnight at 4 oC. The blood samples 
were then homogenised and centrifuged for 
20 min at 3000 g. Serum samples were then 
collected and stored at -80 oC until analysis. 
Serum CRP concentration was measured by 
using Rat hs-CRP ELISA kit, whereas serum 
MDA concentration was measured by using 
2-thiobarbituric acid reactive substances 
(TBARS) assay kit.
Data analysis
Data of serum CRP and MDA concen-
trations were expressed as mean ± standard 
deviation (SD) and analyzed by using 
analysis of variance (ANOVA) continued by 
least significant difference (LSD) post-hoc 
test. A p value less than 0.05 was considered 
significant.
RESULTS 
Serum CRP and MDA concentrations of 
all groups are presented in TABLE 1. After 
nicotine induction at dose of 2 mg/kg BW 
for 28 days (Group II), serum CRP (244.77 ± 
37.95 ng/mL) and MDA (7.29 ± 0.06 mmol/
mL) concentrations of the rats increased 
significantly compared to those without 
nicotine induction on Group I (serum CRP 
concentration was 73.78 ± 20.94 ng/mL and 
serum MDA concentrations was 0.94 ± 0.03 
mmol/mL) (p<0.05). After nicotine induction 
at dose of 2 mg/kg BW and quercetin 
administrations at dose of 25; 50 and 100 mg/
kg BW for 28 days (Group IV-VI), serum CRP 
concentration on Group V (173.39 ± 34.85 ng/
mL) and Group VI (114.15 ± 43.62 ng/mL) 
significantly reduced compared to Group II 
(p<0.05). Moreover serum MDA concentration 
on Group IV (5.95 ± 0.11 mmol/mL), Group 
V (3.93 ± 0.09 mmol/mL) and Group VI (2.14 
± 0.09 mmol/mL) also significantly reduced 
compared to that Group II (p<0.05). After 
nicotine induction at dose of 2 mg/kg BW 
and atorvastatin administration at dose of 5 
mg/kg BW (Group III), serum CRP (166.65 
± 19.06 ng/mL) and MDA (3.02 ± 0.10 mmol/
mL) concentrations also significantly reduced 
compared to that Group II (p<0.05).
Group n Serum CRP(ng/mL)
Serum MDA 
(nmol/mL)
I (normal) 6 73.78 ± 20.94 0.94 ± 0.03
II (nicotine) 6 244.77 ± 37.95 7.29 ± 0.06
III (nicotine + atorvastatin 5 mg/kgBW) 6 166.65 ± 19.06a,b 3.02 ± 0.10a,b
IV (nicotine + quercetin 25 mg/kgBW) 6 241.87 ± 40.30b 5.95 ± 0.11a,b
V (nicotine + quercetin 50 mg/kgBW) 6 173.39 ± 34.85a,b 3.93 ± 0.09a,b
VI (nicotine + quercetin 100 mg/kgBW) 6 114.15 ± 43.62a,b 2.14 ± 0.09a,b
a significantly lower than Group II (p<0.05); b significantly higher than Group I (p<0.05). 
TABLE 1. Serum CRP and MDA concentration in each group
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Correlation r p
Quercetin doses vs CRP 
concentration
-0.506 0.032
Quercetin doses vs MDA 
concentration
-0.622 0.006
Correlation between quercetin doses and 
serum CRP and MDA concentrations on rats 
after nicotine induction was also evaluated 
by using Pearson test of correlation. Negative 
significantly correlation was observed 
between quercetin doses and serum CRP and 
MDA concentrations (TABLE 2). 
TABLE 2.  Correlation between quercetin doses and 
serum CRP and MDA concentrations on 
rats after nicotine induction
DISCUSSION
Endothelial cells have anticoagulant and 
antithrombotic activities. They also regulate 
various mediators including NO which is 
known as endothelium derived relaxing factor 
(EDRF).  NO is synthesized  from L-arginine 
by endothelial  nitric oxide synthase  (eNOS) 
in endothelium. NO plays an important role 
in regulating wide spectrum of cardiovascular 
functions including mediating vasorelaxation, 
inhibiting leukocytes-endothelial adhesion 
and preventing platelet aggregation.7,21,23 
Decrease in NO production caused by 
endothelial dysfunction can lead to an early 
sign of various cardiovascular diseases such 
as atherosclerosis.6,11 
Inflammation has an important role in 
the process of atherosclerosis plaque growth 
until thrombosis occurs that is caused by 
rupture.9,25,26 Macrophage located in the 
plaque contributes to the atherosclerosis 
occurrence by activating NF-κB to stimulate 
proinflammatory genes production.5 Release 
of proinflammatory cytokines such as IL-6, 
IL-1, and TNF-α shows the main regulators 
from CRP, thus CRP concentration in the 
body stand for the indicator of a non specific 
systemic inflammation.9
Nicotine can trigger the release of CRP 
through nAChR in the macrophage which 
located at atherosclerosis plaque. Synthesized 
CRP triggers the increase of free radicals 
which is known as oxidative stress.6 Oxidative 
stress can degrade the NO production by 
deactivating it so that it decreases the NO 
bioavailability.11 In addition, oxidative stress 
causes oxidation of BH4 as one of the NO 
synthetic cofactor. It causes uncoupling 
of eNOS and results in decreasing the 
expression of eNOS and NO production.12 
Oxidative stress also triggers formation of 
lipid peroxidation which damages endothelial 
cell membranes, as marked by the increase of 
MDA concentration in the body.13,14
The result indicated that the nicotine 
administration increased the serum CRP 
concentration as showed the significantly 
higher serum CRP concentration after nicotine 
induction (Grou II) compared to without 
nicotine induction (Group I) (p<0.05). This 
result is in accordance with previous study 
which showed that nicotine induction at dose 
of 2 mg/kg BW cause endothelial dysfunction 
as indicated by the increase of serum CRP 
concentation.5,6,26,27  Nicotine stimulates the 
production of the inflammatory mediators such 
as IL-6, IL-1 and TNF-α as main regulator 
of CRP. Moreover, nicotine induces of CRP 
production of macrophage by activating the 
transcription factor NF-κB.6  
Furthermore, this result also indicated 
that quercetin administration could inhibit the 
increase serum CRP concentration induced 
by nicotine in dose dependent manner (Table 
1). Although, the serum CRP concentration 
after quercetin administration at highest 
dose (100 mg/kg BW on Group VI) was 
higher than that without nicotine induction 
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on Group I. However, this effect of quercetin 
was significantly higher than atorvastatin 
as positive control at dose of 5 mg/kg BW 
(Group III). It was indicated that the quercetin 
administration at dose 100 mg/kg BW had 
not prevented inflammation due to nicotine 
induction, yet. Previous study reported that 
quercetin   reduced the expression of human 
CRP and cardiovascular risk factors  in mice 
in vivo.19 It was also reported that quercetin 
reduced serum level of both TNF-α and CRP 
in models of diabetes.20 
The effect of quercetin on serum CRP 
concentration after nicotine induction was 
parallel with its effect on serum MDA 
concentration. Quercetin administration 
could also inhibit the increase serum MDA 
concentration induced by nicotine in dose 
dependent manner (Table 1 and 2). Previous 
studies reported that nicotine induction at 
the dose of 2 mg/kg BW could stimulate 
inflammation and oxidative stress lead to 
an endothelial dysfunction resulting the 
increase serum MDA concentration.6,7,26,27 
Furthermore, it was reported that quercetin 
has antiinflammatory and antioxidant effects 
which may inhibit the inflammation and 
oxidative stress induced by nicotine.19,20,21
CONCLUSION
It can be concluded that quercetin 
reduces the oxidative status in rats induced 
by nicotine as indicated by the decrease of 
serum CRP and MDA concentrations after 
quercetin administration. Further study will 
be conducted to evaluate the mechanism of 
actions of quercetin in the reduce of oxidative 
status.
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